Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Linked suppression is often used to explain how antigen-specific regulatory T cells (Tregs) might control a complex, multivalent alloimmune response. This review separates linked suppression from bystander suppression and infectious tolerance and considers how direct, indirect, and semi-direct allorecognition define the antigen-presenting cell (APC) substrate on which it can occur. RECENT FINDINGS: Classic transplantation models showed that regulation directed to one antigen can restrain responses to additional antigens when they are physically linked within a graft or presented by the same APC. The breadth and mechanism may vary with donor-antigen burden and the degree of HLA sharing. Relevant interactions appear concentrated in the graft and draining lymph nodes rather than peripheral blood. CTLA-4-dependent B7 removal, local adenosine generation, and spatial organization within APC-rich niches are plausible mechanisms. Small-animal islet, minor-antigen-mismatch, and TCR-transgenic models provide tools to test these variables. Early clinical studies establish feasibility but do not yet prove linked suppression in humans. SUMMARY: Linked suppression is a strong preclinical principle and a useful therapeutic objective, but it is not yet a validated clinical mechanism. Trials should combine product characterization and tracking with linkage-dependent assays, tissue analysis, donor-versus-third-party testing, and protocolized immunosuppression reduction.
No takes yet. Share an insight, caveat, or question.
Chandraker et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: